Since RKIP is an inhibitor of kinases across metastatic cancers, identifying its kinase targets can reveal key signaling mechanisms of invasion and metastasis that are targetable with small molecule inhibitors. This evidence concerns the gene PEBP1 and metastatic malignant neoplasm.